XML 144 R50.htm IDEA: XBRL DOCUMENT
v3.20.4

Grant Revenue (Details) $ in Thousands | 1 Months Ended | 12 Months Ended |
--- | --- | --- | ---
Sep. 30, 2020 USD ($) | Apr. 30, 2020 USD ($) | Sep. 30, 2016 USD ($) contract_option | Dec. 31, 2020 USD ($) | Dec. 31, 2019 USD ($) | Dec. 31, 2018 USD ($) | Jul. 31, 2020 USD ($)
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |
Number of contract options | contract_option |  |  | 3 |  |  |  |
Revenues |  |  |  | $ 803,395 | $ 60,209 | $ 135,068 |
Deferred revenue |  |  |  | 4,044,612 | 202,305 |  |
Grant revenue |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |
Revenues |  |  |  | 528,905 | 12,173 | 12,556 |
Deferred revenue |  |  |  | 5,261 | 2,777 |  |
BARDA |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |
Award amount |  | $ 483,300 | $ 125,800 |  |  |  |
Other Commitment |  |  |  |  |  |  | $ 471,600
Amount committed for funding |  |  |  | 444,300 |  |  |
Number of contract options exercised | contract_option |  |  | 4 |  |  |  |
BARDA | Minimum |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |
Award amount |  |  |  | 483,300 |  |  |
BARDA | Maximum |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |
Award amount |  |  |  | 954,900 |  |  |
BARDA | Contract options |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |
Available funding |  |  |  | 8,400 |  |  |
Amount committed for funding |  |  |  | 70,800 |  |  |
BARDA | Grant revenue |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |
Revenues |  |  |  | 521,652 | 7,608 | 6,736 |
DARPA |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |
Award amount | $ 56,400 |  |  |  |  |  |
DARPA | Contract options |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |
Available funding |  |  |  | 51,400 |  |  |
Amount committed for funding |  |  |  | 4,600 |  |  |
The Bill & Melinda Gates Foundation | Initial project |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |
Available funding |  |  |  | 11,400 |  |  |
Deferred revenue |  |  |  | 80,000 |  |  |
Other Grant Revenue | Grant revenue |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |
Revenues |  |  |  | $ 7,253 | $ 4,565 | $ 5,820 |

X
- Definition Revenue From Grants, Current Funding Capacity + References No definition available. + Details
Name: | mrna_RevenueFromGrantsCurrentFundingCapacity
Namespace Prefix: | mrna_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue From Grants, Maximum Award + References No definition available. + Details
Name: | mrna_RevenueFromGrantsMaximumAward
Namespace Prefix: | mrna_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue From Grants, Number Of Contract Options + References No definition available. + Details
Name: | mrna_RevenueFromGrantsNumberOfContractOptions
Namespace Prefix: | mrna_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Revenue From Grants, Number Of Contract Options Exercised + References No definition available. + Details
Name: | mrna_RevenueFromGrantsNumberOfContractOptionsExercised
Namespace Prefix: | mrna_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Revenue From Grants, Remaining Funding Capacity + References No definition available. + Details
Name: | mrna_RevenueFromGrantsRemainingFundingCapacity
Namespace Prefix: | mrna_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions. + References No definition available. + Details
Name: | us-gaap_OtherCommitment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_GrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mrna_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_ContractOptionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mrna_DefenseAdvancedResearchProjectsAgencyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mrna_TheBillAndMelindaGatesFoundationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_InitialProjectMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=mrna_OtherGrantRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |